The shift to risk-based quality management (RBQM) in clinical trials offers market opportunities in proactive risk strategies, focusing on patient safety and data integrity. Emphasizing digital ...
Mangrove Management Partners (MMP), its affiliate The Vascular Care Group (TVCG), and American Vascular Associates (AVA) today thanked the Centers for Medicare & Medicaid Services (CMS), MedPAC, and ...
Global Veterinary Software Market OverviewThe global veterinary software market is poised for substantial expansion, with an expected growth rate of 8–10% between 2024 and 2029. As veterinary ...
D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of ...
Seasoned Pharmaceutical leader bringing over 24 years of experience in clinical development across autoimmune, metabolic, ...
Physicians and researchers from Ivy Fertility, a globally-recognized network of fertility centers, shared cutting-edge presentations and posters at the 2025 American Society for Reproductive Medicine ...
Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology indications, today announced the ...
It is a story of returns to Italy, of startup enthusiasts crossing paths, of passionate individuals meeting by chance during the hackathon organized by Spicy in East Naples and deciding to ...
University of California, Berkeley and University of California, San Francisco researchers today released Pillar (Pillar-0), an open-source AI model that analyzes medical images and recognizes ...
Oakmark spotlights six stocks driving AI, M&A, and analytics upside, while navigating debt, guidance cuts, and valuation ...
The Texas Tribune on MSN
A small Texas think tank cultivated COVID dissidents. Now they’re running U.S. health policy.
People with ties to Brownstone Institute have significant authority over access to vaccines and scientific research.
The CNPV program aims to reduce drug review times to 1-2 months, raising concerns about safety and regulatory scrutiny. Critics argue that accelerated timelines may lead to safety issues and strain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback